<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30043912</article-id><article-id pub-id-type="pmc">6089128</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0244</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Lidocaine and Pinacidil Added to Blood <italic>versus</italic>
Crystalloid Cardioplegic Solutions: Study in Isolated Hearts</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>do Carmo</surname><given-names>Helison Pereira</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Reichert</surname><given-names>Karla</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>PhD</role></contrib><contrib contrib-type="author"><name><surname>de Carvalho</surname><given-names>Daniela Di&#x000f3;genes</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MSc</role></contrib><contrib contrib-type="author"><name><surname>Silveira-Filho</surname><given-names>Lindemberg da Mota</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Vilarinho</surname><given-names>Karlos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Oliveira</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Petrucci</surname><given-names>Orlando</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><aff id="aff1">
<label>1</label>Universidade Estadual de Campinas (Unicamp), Campinas, SP,
Brazil.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Helison Pereira do Carmo, Universidade
Estadual de Campinas - Cirurgia, Rua Cinco de Junho, 350 - NMCE/FCM-015,
Campinas, SP, Brazil - Zip code: 13083-877. E-mail:
<email>helison.rafael@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>May-Jun</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>May-Jun</season><year>2018</year></pub-date><volume>33</volume><issue>3</issue><fpage>211</fpage><lpage>216</lpage><history><date date-type="received"><day>20</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The present study aimed the functional recovery evaluation after long term of
cardiac arrest induced by Custodiol (crystalloid-based)
<italic>versus</italic> del Nido (blood-based) solutions, both added
lidocaine and pinacidil as cardioplegic agents. Experiments were performed
in isolated rat heart perfusion models.</p></sec><sec><title>Methods</title><p>Male rat heart perfusions, according to Langendorff technique, were induced
to cause 3 hours of cardiac arrest with a single dose. The hearts were
assigned to one of the following three groups: (I) control; (II)
Custodiol-LP; and (III) del Nido-LP. They were evaluated after ischemia
throughout 90 minutes of reperfusion. Left ventricular contractility
function was reported as percentage of recovery, expressed by developed
pressure, maximum dP/dt, minimum dP/dt, and rate pressure product variables.
In addition, coronary resistance and myocardial injury marker by
alpha-fodrin degradation were also evaluated.</p></sec><sec><title>Results</title><p>At 90 minutes of reperfusion, both solutions had superior left ventricular
contractile recovery function than the control group. Del Nido-LP was
superior to Custodiol-LP in maximum dP/dt (46%&#x000b1;8 <italic>vs</italic>.
67%&#x000b1;7, <italic>P</italic>&#x0003c;0.05) and minimum dP/dt (31%&#x000b1;4
<italic>vs</italic>. 51%&#x000b1;9, <italic>P</italic>&#x0003c;0.05)
variables. Coronary resistance was lower in del Nido-LP group than in
Custodiol-LP (395%&#x000b1;50 <italic>vs</italic>. 307%&#x000b1;13,
<italic>P</italic>&#x0003c;0.05), as well as alpha-fodrin degradation, with
lower levels in del Nido-LP group (<italic>P</italic>&#x0003c;0.05).</p></sec><sec><title>Conclusion</title><p>Del Nido-LP cardioplegia showed higher functional recovery after 3 hours of
ischemia. The analysis of alpha-fodrin degradation showed del Nido-LP
solution provided greater protection against myocardial ischemia and
reperfusion (IR) in this experimental model.</p></sec></abstract><kwd-group><kwd>Models, Animal</kwd><kwd>Cardioplegic Solutions</kwd><kwd>Myocardial Reperfusion Injury</kwd><kwd>Heart Arrest, Induced/Methods</kwd></kwd-group><funding-group><award-group><funding-source>Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de
S&#x000e3;o Paulo</funding-source><award-id>2012/09130-1</award-id></award-group><funding-statement>Financial support: Funda&#x000e7;&#x000e3;o de Amparo &#x000e0;
Pesquisa do Estado de S&#x000e3;o Paulo (FAPESP)
2012/09130-1.</funding-statement></funding-group></article-meta></front><body><table-wrap id="t2" orientation="portrait" position="float"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ATP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Adenosine
triphosphate</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CEUA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ethics Committee on the
Use of Animals</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">COBEA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Brazilian Council for
Animal Experimentation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary resistance</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ischemia and
reperfusion</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RPP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Rate pressure
product</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SEM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard error of
mean</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Unicamp</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Universidade Estadual de
Campinas</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Cardioplegic solution administration in open-heart surgeries has been the main
strategy enable to antagonize the effects of global ischemia and reperfusion (IR).
Cardioplegic arrest in combination with hypothermia corresponds to a standard method
to reduce cardiac metabolism during the period of absence of oxygen and substrate,
avoiding the collapse of contractile function after
reperfusion<sup>[</sup><sup><xref rid="r1" ref-type="bibr">1</xref></sup><sup>,</sup><sup><xref rid="r2" ref-type="bibr">2</xref></sup><sup>]</sup>.</p><p>Despite being essential, this scientific field faces a major challenge in determining
a single type of cardioplegic solution protocol amidst a variety of surgical
procedures. A pharmacological approach to drugs that act as cardioplegic agents
makes this puzzle even more difficult to understand. In the presence of cardioplegic
agents, these solutions can block or open ion channels present in the sarcolemma,
influencing on the ion dynamic between extra and intracellular means.</p><p>In the present study, two cardioplegic agents with distinct actions on ion channels
were evaluated, followed by (I) pinacidil, a potassium channel opener, and (II)
lidocaine, a sodium channel blocker. Rationally, two different types of solution,
very eminent in clinical practice, were elected to drive these drugs on myocardium
during global ischemia<sup>[</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>]</sup>.</p><p>Firstly, Custodiol solution (Custodiol<sup>&#x000ae;</sup>-HTK), commonly known as HTK
solution (histidine/tryptophan/alpha-ketoglutarate) and which has been used
primarily in organ preservation, was conceived as an alternative to crystalloid
hyperkalemic cardioplegic solutions<sup>[</sup><sup><xref rid="r4" ref-type="bibr">4</xref></sup><sup>,</sup><sup><xref rid="r5" ref-type="bibr">5</xref></sup><sup>]</sup>. Custodiol solution has been used in some countries
as the first choice for conventional cardiac surgeries, mainly in myocardial
preservation<sup>[</sup><sup><xref rid="r6" ref-type="bibr">6</xref></sup><sup>]</sup>. It is considered a type of microplegia or
cardioplegia solution with intracellular action due to reduction of potassium,
sodium, and calcium concentration, resulting in cardiac arrest by polarization and
avoiding damages from hypercontractures related to the depolarized arrest. In
addition, Custodiol solution has an important buffering effect attributed to the
amino acid histidine, which is important in controlling the balance of hydrogen ion
levels released during a long period of ischemia<sup>[</sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>,</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>]</sup>.</p><p>Secondly, del Nido cardioplegia, initially developed to be used in a single dose in
neonatal surgeries, is classified as a modified hyperkalemic type due to high
potassium concentration, although the lidocaine in its composition avoids the ionic
imbalance by blocking sodium current flow<sup>[</sup><sup><xref rid="r9" ref-type="bibr">9</xref></sup><sup>-</sup><sup><xref rid="r11" ref-type="bibr">11</xref></sup><sup>]</sup>. This sodium channel blockage prevents
intracellular calcium overload, avoiding contractile dysfunction after
reperfusion<sup>[</sup><sup><xref rid="r11" ref-type="bibr">11</xref></sup><sup>]</sup>. Lidocaine is a selective and reversible blocker
frequently used in clinical practice for the treatment of ventricular tachycardia
and also has been assisted recovery hearts submitted to IR in experimental
models<sup>[</sup><sup><xref rid="r12" ref-type="bibr">12</xref></sup><sup>,</sup><sup><xref rid="r13" ref-type="bibr">13</xref></sup><sup>]</sup>.</p><p>This study aimed to evaluate cardioplegic solutions under pharmacological
modification. Pinacidil was added to both solutions and lidocaine only to the
Custodiol solution, since del Nido cardioplegia original formulation already has
this agent. Cardioplegic solutions were termed as Custodiol-LP and del Nido-LP. The
main goal was to evaluate functional recovery after 3 hours of ischemia and 90
minutes of reperfusion. Moreover, cardiomyocyte integrity by alpha-fodrin
degradation was also evaluated from heart samples collected at the end of the
protocol.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Animals</title><p>A total of 18 male Wistar rats weighing 250-350 g were used in this study, which
was approved by the Ethics Committee on the Use of Animals (CEUA) of the
Universidade Estadual de Campinas (Unicamp) and follows the ethic statements of
the "Guide to the Care and Use of Laboratory Animals", published by the National
Institute of Health of USA (NIH Publication No. 85-23, revised 1996), and the
Brazilian Council for Animal Experimentation (COBEA).</p></sec><sec><title>Surgical Protocol for Heart Perfusion</title><p>All animals received sodium thiopental anaesthesia (80 mg/kg) and sodium heparin
(2,500 IU/kg) intraperitoneally. Then, a bilateral thoracotomy was performed
exposing the heart to cardiectomy. The aorta was fixed to the system cannula
with silk suture 4-0 and the perfusion was kept under constant pressure
throughout the experiment. The catheter with latex balloon connected to the
transducer pressure probe was inserted through the mitral valve and allocated to
the left ventricle (LV). LV functional measurements of developed pressure,
maximum dP/dt, minimum dP/dt, and rate pressure product (RPP) and the coronary
resistance (CR) were done.</p></sec><sec><title>Experimental Groups and Protocol</title><p>The hearts were assigned to one of the following three groups: control (n=4),
Custodiol-LP (n=6) and del Nido-LP (n=6). They were initially perfused for 10
minutes stabilization to obtain baseline measurements. Cardiac arrest was
induced with a single dose of cardioplegia (30 ml/kg), and the hearts were
maintained in global ischemia at 4&#x000b0;C for 3 hours. Reperfusion was performed by
re-establishing the heart perfusion.</p></sec><sec><title>Cardioplegic Solutions Preparation</title><p>The Custodiol solution was acquired from a commercial vendor (<xref rid="t1" ref-type="table">Table 1</xref>). Blood cardioplegia del Nido was
prepared with autologous blood collected directly from the thoracic cavity after
heart explantation 1:4 (blood:solution) (<xref rid="t1" ref-type="table">Table
1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Composition of cardioplegic solutions.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="70%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Components (mM)</th><th align="center" rowspan="1" colspan="1">Custodiol-LP</th><th align="center" rowspan="1" colspan="1">del Nido-LP</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Carrier</td><td align="center" rowspan="1" colspan="1">Sterile water</td><td align="center" rowspan="1" colspan="1">Plasma-Lyte A<sup>&#x000ae;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Blood:cardioplegia</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1:4</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium chloride</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Histidine</td><td align="center" rowspan="1" colspan="1">180</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Histidine-HCl</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Magnesium chloride</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Magnesium sulfate</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">6.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Mannitol</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">13.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Potassium chloride</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">24.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Potassium hydrogen 2-ketoglutarate</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium acetate trihydrate</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">20.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium bicarbonate</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">13.79</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium chloride</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">91.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium gluconate</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">17.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Tryptophan</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" colspan="3" rowspan="1">Drugs concentration (del Nido-LP
without added blood)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lidocaine</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Pinacidil</td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">0.5</td></tr></tbody></table></table-wrap></sec><sec><title>Immunoblot by Western Blot Technique</title><p>The total protein extract with 50 &#x000b5;g per left ventricular sample was
applied on 12% polyacrylamide gel (SDS-PAGE). Separation of the proteins of
interest was performed by electrophoresis in mini-gel cell (Mini-PROTEAN II
Cel&#x000ae; Bio-Rad) with buffer solution for electrophoresis previously
diluted. Proteins were then transferred to a nitrocellulose membrane using
electrotransfer equipment (Trans-Blot&#x000ae; Turbo(tm) Transfer System
Bio-Rad). After transference, membranes were blocked with milk for subsequent
incubation with primary alpha-fodrin (Abcam&#x000ae;, ab39165) at 4&#x000b0;C with
constant stirring overnight (14-16 hours). These membranes were then washed with
PBS solution and incubated in a chemiluminescent solution (Thermo Scientific
Pierce ECL Western Blotting Substrate). Images were obtained by the
multi-function system (Gel Logic Imaging System&#x000ae;, Rochester, NY, USA) to
capture chemiluminescent reactions. All images were quantified by densitometry
and normalized by colourimetric method with Ponceau<sup>[</sup><sup><xref rid="r14" ref-type="bibr">14</xref></sup><sup>]</sup>.</p></sec><sec><title>Statistical Analysis</title><p>All data were expressed as percentage of recovery and as mean and standard error
of mean (SEM). The hemodynamic data were normalized with baseline values.
Analyses were performed by 2-way ANOVA with Sidak's <italic>post-hoc</italic>
test for multiple comparisons. Comparison of protein expression was performed
using non-parametric Student t-test. Statistical significance was assumed
<italic>P</italic>&#x0003c;0.05. All statistical analyses were performed using
GraphPad&#x000ae; Prism 6 software.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Functional Left Ventricle Analysis</title><p>Two hearts from the control group were excluded due to ventricular fibrillation
and no beating recovery after ischemia. Lower levels of developed pressure
(<xref ref-type="fig" rid="f1">Figure 1A</xref>) and RPP (<xref ref-type="fig" rid="f1">Figure 1B</xref>) recovery were found in the control
group than in Custodiol-LP and del Nido-LP groups, respectively. However, no
relevant differences among the cardioplegic solution groups were found with
these variables. Relevant lower levels of maximum dP/dt (<xref ref-type="fig" rid="f1">Figure 1C</xref>) and minimum dP/dt (<xref ref-type="fig" rid="f1">Figure 1D</xref>) were found in the control group than in Custodiol-LP and
del Nido-LP groups, respectively. However, at 90 minutes of reperfusion, higher
levels of maximum dP/dt (<xref ref-type="fig" rid="f1">Figure 1C</xref>) and
minimum dP/dt (<xref ref-type="fig" rid="f1">Figure 1D</xref>) were found in del
Nido-LP group than in Custodiol-LP.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Left ventricular function data expressed as percentage of recovery
after 3 hours. (A) Developed pressure. (B) Rate pressure product.
(C) Maximum dP/dt. (D) Minimum dP/dt. All values are expressed as
mean and standard error of mean (SEM) (error bars). Analyses were
performed by 2-way ANOVA with Sidak's post-hoc test for multiple
comparisons (*P &#x0003c; 0.05 compared to del Nido group). Six animals
per group.</p></caption><graphic xlink:href="rbccv-33-03-0211-g01"/></fig>
</p></sec><sec><title>Coronary Resistance</title><p>CR levels found in the control group were higher than in Custodiol-LP group up to
60 minutes of reperfusion (<xref ref-type="fig" rid="f2">Figure 2</xref>).
Compared to del Nido-LP group, the control group showed high levels of CR
throughout reperfusion. However, del Nido-LP group showed lower levels of CR
than Custodiol-LP group at 90 minutes of reperfusion (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Coronary resistance data expressed as percentage of recovery after 3
hours. All values are expressed as mean and standard error of mean
(SEM) (error bars). Analyses were performed by 2-way ANOVA with
Sidak's post-hoc test for multiple comparisons (*P&#x0003c;0.05 compared
to del Nido group). Six animals per group.</p></caption><graphic xlink:href="rbccv-33-03-0211-g02"/></fig>
</p></sec><sec><title>Protein Expression by Western Blot Technique</title><p>Higher degradation of alpha-fodrin expression was found in Custodiol-LP group
than in del Nido group in samples collected after 3 hours of ischemia and 90
minutes of reperfusion (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Representative Western blot results for alpha-fodrin. All values are
expressed as mean, standard error of mean (SEM) (error bars), and
arbitrary units. Analyses were performed by t-test (*P&#x0003c;0.05).
Four animals per group.</p></caption><graphic xlink:href="rbccv-33-03-0211-g03"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Myocardial global IR insult is well known to promote multifactorial effects on
cellular metabolism resulting in irreversible damage to the heart function.
Cardioplegic solutions with pharmacological combination as an alternative to provide
further myocardial protection have encouraged researchers to carry out different
combinations<sup>[</sup><sup><xref rid="r15" ref-type="bibr">15</xref></sup><sup>]</sup>. Therefore, the present study evaluated
pharmacological modifications with sodium inhibitor channels and potassium channel
openers added to clinical relevant cardioplegic solutions, Custodiol and del
Nido.</p><p>The potassium channel opener pinacidil has two main effects: vasodilatation and
contractility reduction, due to its effect on potassium efflux avoiding calcium
overload into the cardiomyocytes<sup>[</sup><sup><xref rid="r16" ref-type="bibr">16</xref></sup><sup>]</sup>. In experimental models, pinacidil induced
cardiac arrest by polarization, consequently reducing the adenosine triphosphate
(ATP) consumption, compared to the cardiac arrest induced by
depolarization<sup>[</sup><sup><xref rid="r17" ref-type="bibr">17</xref></sup><sup>,</sup><sup><xref rid="r18" ref-type="bibr">18</xref></sup><sup>]</sup>. Pinacidil has a non-selective pharmacological
effect regarding the potassium channels' location, being able to activate them in
the sarcolemma and mitochondria, since both have an important role in myocardial
protection<sup>[</sup><sup><xref rid="r17" ref-type="bibr">17</xref></sup><sup>,</sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>]</sup>. Differently, lidocaine is a reversible sodium
channel blocker which has a pharmacological effect on calcium overload, preventing
sodium-calcium exchanger reverse-mode action during IR<sup>[</sup><sup><xref rid="r9" ref-type="bibr">9</xref></sup><sup>,</sup><sup><xref rid="r10" ref-type="bibr">10</xref></sup><sup>]</sup>. In combination, these
cardioplegic agents might improve cardiac resistance against long-term ischemia.</p><p>Custodiol-LP showed detrimental effects on cardiac function by the maximum and
minimum dP/dt at 90 minutes of reperfusion compared to del Nido-LP. However,
developed pressure and RPP parameters were similar throughout reperfusion time. CR
analysis showed Custodiol-LP group with higher levels than del Nido-LP and marked
reduction of coronary flow after 90 minutes of reperfusion.</p><p>The superiority of del Nido-LP solution may be associated with its greater ability to
protect the myocardium over prolonged ischemia. The immunoblot assay performed by
Western blot technique showed alpha-fodrin significant degradation in Custodiol-LP
group compared to del Nido-LP. Alpha-fodrin present in extracellular matrix is
consumed as a substrate for calpains after IR. The increase of calpain activity is
correlated with myocardial injury and loss of contractile
function<sup>[</sup><sup><xref rid="r20" ref-type="bibr">20</xref></sup><sup>-</sup><sup><xref rid="r22" ref-type="bibr">22</xref></sup><sup>]</sup>. Therefore, alpha-fodrin degradation is an indirect
marker for cell integrity.</p><p>According to our findings, the addition of pharmacological agents to cardioplegic
solutions showed greater myocardial protection in del Nido-LP group than in
Custodiol-LP. Other components present in this solution may have possibly
collaborated for these results. A single dose of the del Nido original formulation
per se has shown great efficacy in pediatric and adult surgeries; perhaps, new
solution proposals to induce long periods of ischemia should be based on its
composition.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The addition of cardioplegic agents pinacidil and lidocaine provided greater
protective capacity to del Nido-LP solution than to Custodiol-LP in hearts submitted
to 3 hours of ischemia and 90 minutes of reperfusion. Contractile function data,
according to variables of maximum dP/dt, minimum dP/dt and CR, showed a higher
percentage of recovery in del Nido-LP group. Also, lower levels of alpha-fodrin
degradation in del Nido-LP can support these findings showing higher myocardial
protection against IR injury.</p><table-wrap id="t3" orientation="portrait" position="float"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">HPC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KR</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DDC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LMSF</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KV</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PO</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OP</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Universidade Estadual de Campinas (Unicamp),
Campinas, SP, Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>Financial support: Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado
de S&#x000e3;o Paulo (FAPESP) 2012/09130-1.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>ZG</given-names></name><name><surname>Yarborough</surname><given-names>DE</given-names></name><name><surname>Jarvis</surname><given-names>BL</given-names></name><name><surname>Sistino</surname><given-names>JJ</given-names></name></person-group><article-title>Evidence-based medicine and myocardial protection: where is the
evidence?</article-title><source>Perfusion</source><year>2015</year><volume>30</volume><issue>5</issue><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">25298053</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suleiman</surname><given-names>MS</given-names></name><name><surname>Hancock</surname><given-names>M</given-names></name><name><surname>Shukla</surname><given-names>R</given-names></name><name><surname>Rajakaruna</surname><given-names>C</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name></person-group><article-title>Cardioplegic strategies to protect the hypertrophic heart during
cardiac surgery</article-title><source>Perfusion</source><year>2011</year><volume>26</volume><issue>Suppl 1</issue><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">21933822</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>B</given-names></name><name><surname>Shann</surname><given-names>KG</given-names></name><name><surname>Fitzgerald</surname><given-names>D</given-names></name><name><surname>Mejak</surname><given-names>B</given-names></name><name><surname>Likosky</surname><given-names>DS</given-names></name><name><surname>Puis</surname><given-names>L</given-names></name><etal/><collab>American Society of ExtraCorporeal Technology's International
Consortium for Evidence-Based Perfusion and Pediatric Perfusion
Committee</collab></person-group><article-title>International pediatric perfusion practice: 2011 survey
results</article-title><source>J Extra Corpor Technol</source><year>2012</year><volume>44</volume><issue>4</issue><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">23441558</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groenewoud</surname><given-names>AF</given-names></name><name><surname>Buchholz</surname><given-names>B</given-names></name><name><surname>Gubernatis</surname><given-names>F</given-names></name><name><surname>H&#x000f6;lscher</surname><given-names>M</given-names></name><name><surname>Hoyer</surname><given-names>J</given-names></name><name><surname>Isemer</surname><given-names>F</given-names></name><etal/></person-group><article-title>First results of the multicenter study of HTK protection for
kidney transplants</article-title><source>Transplant Proc</source><year>1990</year><volume>22</volume><issue>5</issue><fpage>2212</fpage><lpage>2212</lpage><pub-id pub-id-type="pmid">2219347</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;lscher</surname><given-names>M</given-names></name><name><surname>Groenewoud</surname><given-names>AF</given-names></name></person-group><article-title>Current status of the HTK solution of Bretschneider in organ
preservation</article-title><source>Transplant Proc</source><year>1991</year><volume>23</volume><issue>5</issue><fpage>2334</fpage><lpage>2337</lpage><pub-id pub-id-type="pmid">1926380</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edelman</surname><given-names>JJ</given-names></name><name><surname>Seco</surname><given-names>M</given-names></name><name><surname>Dunne</surname><given-names>B</given-names></name><name><surname>Matzelle</surname><given-names>SJ</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Joshi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Custodiol for myocardial protection and preservation: a
systematic review</article-title><source>Ann Cardiothorac Surg</source><year>2013</year><volume>2</volume><issue>6</issue><fpage>717</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">24349972</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>CS</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Shigemura</surname><given-names>N</given-names></name><name><surname>Stolz</surname><given-names>DB</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Superior myocardial preservation with HTK solution over Celsior
in rat hearts with prolonged cold ischemia</article-title><source>Surgery</source><year>2010</year><volume>148</volume><issue>2</issue><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">20627336</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>MA</given-names></name><name><surname>Brandi</surname><given-names>AC</given-names></name><name><surname>Santos</surname><given-names>CA</given-names></name><name><surname>Botelho</surname><given-names>PH</given-names></name><name><surname>Cortez</surname><given-names>JL</given-names></name><name><surname>Braile</surname><given-names>DM</given-names></name></person-group><article-title>Modes of induced cardiac arrest: hyperkalemia and
hypocalcemia-literature review</article-title><source>Rev Bras Cir Cardiovasc</source><year>2014</year><volume>29</volume><issue>3</issue><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">25372919</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Blenes</surname><given-names>SB</given-names></name><name><surname>Friesen</surname><given-names>CH</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Howlett</surname><given-names>S</given-names></name></person-group><article-title>Protecting the aged heart during cardiac surgery: the potential
benefits of del Nido cardioplegia</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>141</volume><issue>3</issue><fpage>762</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">20656301</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govindapillai</surname><given-names>A</given-names></name><name><surname>Hua</surname><given-names>R</given-names></name><name><surname>Rose</surname><given-names>R</given-names></name><name><surname>Friesen</surname><given-names>CH</given-names></name><name><surname>O'Blenes</surname><given-names>SB</given-names></name></person-group><article-title>Protecting the aged heart during cardiac surgery: use of del Nido
cardioplegia provides superior functional recovery in isolated
hearts</article-title><source>J Thorac Cardiovasc Surg</source><year>2013</year><volume>146</volume><issue>4</issue><fpage>940</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">23953721</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matte</surname><given-names>GS</given-names></name><name><surname>del Nido</surname><given-names>PJ</given-names></name></person-group><article-title>History and use of del Nido cardioplegia solution at Boston
Children's Hospital</article-title><source>J Extra Corpor Technol</source><year>2012</year><volume>44</volume><issue>3</issue><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">23198389</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betri&#x000e1;n Blasco</surname><given-names>P</given-names></name><name><surname>Ant&#x000fa;nez Jim&#x000e9;nez</surname><given-names>MI</given-names></name><name><surname>Falc&#x000f3;n Gonz&#x000e1;lez</surname><given-names>LH</given-names></name><name><surname>Su&#x000e1;rez Cabrera</surname><given-names>P</given-names></name></person-group><article-title>Neonatal life-threatening arrhythmia responding to lidocaine, a
probable LQTS3</article-title><source>Int J Cardiol</source><year>2007</year><volume>117</volume><issue>2</issue><fpage>e61</fpage><lpage>e63</lpage><pub-id pub-id-type="pmid">17320211</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Emous</surname><given-names>JG</given-names></name><name><surname>Nederhoff</surname><given-names>MG</given-names></name><name><surname>Ruigrok</surname><given-names>TJ</given-names></name><name><surname>van Echteld</surname><given-names>CJ</given-names></name></person-group><article-title>The role of the Na+ channel in the accumulation of intracellular
Na+ during myocardial ischemia: consequences for post-ischemic
recovery</article-title><source>J Mol Cell Cardiol</source><year>1997</year><volume>29</volume><issue>1</issue><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">9040024</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichert</surname><given-names>K</given-names></name><name><surname>Pereira do Carmo</surname><given-names>HR</given-names></name><name><surname>Galluce Torina</surname><given-names>A</given-names></name><name><surname>Di&#x000f3;genes de Carvalho</surname><given-names>D</given-names></name><name><surname>Carvalho Sposito</surname><given-names>A</given-names></name><name><surname>Souza Vilarinho</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Atorvastatin improves ventricular remodeling after myocardial
infarction by interfering with collagen metabolism</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>11</issue><elocation-id>e0166845</elocation-id><pub-id pub-id-type="pmid">27880844</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>F</given-names></name></person-group><article-title>Myocardial protection in cardiac surgery: a historical review
from the beginning to the current topics</article-title><source>Gen Thorac Cardiovasc Surg</source><year>2013</year><volume>61</volume><issue>9</issue><fpage>485</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">23877427</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawton</surname><given-names>JS</given-names></name><name><surname>Harrington</surname><given-names>GC</given-names></name><name><surname>Allen</surname><given-names>CT</given-names></name><name><surname>Hsia</surname><given-names>PW</given-names></name><name><surname>Damiano Jr</surname><given-names>RJ</given-names></name></person-group><article-title>Myocardial protection with pinacidil cardioplegia in the
blood-perfused heart</article-title><source>Ann Thorac Surg</source><year>1996</year><volume>61</volume><issue>6</issue><fpage>1680</fpage><lpage>1688</lpage><pub-id pub-id-type="pmid">8651767</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name></person-group><article-title>Prolonged donor heart preservation with pinacidil: the role of
mitochondria and the mitochondrial adenosine triphosphate-sensitive
potassium channel.</article-title><source>J Thorac Cardiovasc Surg</source><year>2010</year><volume>139</volume><issue>4</issue><fpage>1057</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">20304147</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikizler</surname><given-names>M</given-names></name><name><surname>Dernek</surname><given-names>S</given-names></name><name><surname>Sevin</surname><given-names>B</given-names></name><name><surname>Maxey</surname><given-names>TS</given-names></name><name><surname>Kural</surname><given-names>T</given-names></name></person-group><article-title>Improved myocardial function with the addition of pinacidil to
custodiol</article-title><source>Transplantation</source><year>2002</year><volume>74</volume><issue>12</issue><fpage>1666</fpage><lpage>1671</lpage><pub-id pub-id-type="pmid">12499877</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testai</surname><given-names>L</given-names></name><name><surname>Rapposelli</surname><given-names>S</given-names></name><name><surname>Calderone</surname><given-names>V</given-names></name></person-group><article-title>Cardiac ATP-sensitive potassium channels: a potential target for
an anti-ischaemic pharmacological strategy</article-title><source>Cardiovasc Hematol Agents Med Chem</source><year>2007</year><volume>5</volume><issue>1</issue><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17266550</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Won</surname><given-names>DJ</given-names></name><name><surname>Krajewski</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>RA</given-names></name></person-group><article-title>Calpain and mitochondria in ischemia/reperfusion
injury</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>32</issue><fpage>29181</fpage><lpage>29186</lpage><pub-id pub-id-type="pmid">12042324</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>RA</given-names></name><name><surname>Campbell</surname><given-names>RL</given-names></name><name><surname>Davies</surname><given-names>PL</given-names></name></person-group><article-title>Calcium-bound structure of calpain and its mechanism of
inhibition by calpastatin</article-title><source>Nature</source><year>2008</year><volume>456</volume><issue>7220</issue><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">19020623</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernando</surname><given-names>V</given-names></name><name><surname>Inserte</surname><given-names>J</given-names></name><name><surname>Sartorio</surname><given-names>CL</given-names></name><name><surname>Parra</surname><given-names>VM</given-names></name><name><surname>Poncelas-Nozal</surname><given-names>M</given-names></name><name><surname>Garcia-Dorado</surname><given-names>D</given-names></name></person-group><article-title>Calpain translocation and activation as pharmacological targets
during myocardial ischemia/reperfusion</article-title><source>J Mol Cell Cardiol</source><year>2010</year><volume>49</volume><issue>2</issue><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">20211186</pub-id></element-citation></ref></ref-list></back></article>